Last year, oral amycretin was shown in a phase 1 trial to achieve approximately 10% weight loss at a daily dose of 50mg at 12 weeks, with patients taking 100mg per day seeing a 13% reduction.

The drug, called amycretin and codenamed NN9487 ... patients out of a total planned enrolment of 144. After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Beyond semaglutide, Novo Nordisk is developing other drugs in its core areas of diabetes and weight loss. The company's pipeline features several promising compounds, including Amycretin.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Mounjaro’s been great,” the comedian said in an Instagram video. “I’m having a really good experience with it and I wanted to ...

I’m one of the millions of people trying to keep the weight off without taking expensive drugs like Mounjaro or Ozempic for ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...